Phase 3 data show delayed time to relapse and maintained tic improvement with investigational, first-in-class mechanism targeting dopamine pathway Phase 3 results published in JAMA Neurology showed that ecopipam, an investigational, first-in-class dopamine-1 (D1) receptor antagonist, delayed time to relapse compared to placebo and maintained … Read more
— Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. — The late‑stage program in a high-need, specialized area of neuroscience expands Teva’s innovative medicines pipeline, aligns with commercial strengths and supports both near‑ and long‑term growth. — Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up … Read more
Novel composition-of-matter patent supports formulation innovation as development advances and patient access expand CHICAGO — April 9, 2026 —Emalex Biosciences today announced that the U.S. Patent and Trademark Office issued a patent covering an orally disintegrating tablet (ODT) formulation of ecopipam, an investigational D1 receptor … Read more
Study opens pathway to investigational therapy for patients with Tourette syndrome who have exhausted approved treatments CHICAGO — March 9, 2026 — Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist … Read more
Chicago biotech focused on CNS disorders to submit New Drug Application in December for first-in-class treatment CHICAGO — October 8, 2025 — Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company’s Expanded Access Program (EAP) for ecopipam, an investigational … Read more